China Medical System Holdings Limited announced that on 24 August 2023, the Group through a wholly-owned subsidiary of the Company entered into a Collaboration Agreement with Nanjing NeuroDawn Pharmaceutical Co. Ltd. for anti-ischemic stroke brain cytoprotectant and class 1 innovative drug Y-3 injection. In accordance with the Agreement, the Group gained an exclusive promotion right of the Product in Mainland China, Hong Kong Special Administrative Region and Macao Special Administrative Region.

The term of the Agreement is permanent. Y-3 INJECTION. Y-3 Injection is a Class 1 innovative drug - small molecule compound, which is used to alleviate neurological symptoms and dysfunction of daily activities caused by acute ischemic stroke.

The mechanism of action of the Product is to diss associate PSD-95 and nNOS coupling and activate a2-GABAA receptors. With dual-target intervention at the same time and its clear mechanism of action, the Product is conducive to exerting brain cytoprotection effects. Meanwhile, the Product has a rapid anti-depression and anti-an anxiety function, and is expected to become the first new type of brain cytoprotectant that treats both stroke and post-stroke depression.

The Product has compound and formulation patents in China. The number of new cases of ischemic stroke in China was approximately 2.87 million in 2019, and the incidence rate substantially increased by 226.5% from 1990 to 2019, with a large patient population. Stroke has the characteristics of high disability rate and heavy economic burden.

There is an urgent clinical need for evidence-based drugs to reduce family and social burdens. Y-3 Injection has significant potential value in improving the long-term neurological function and overall prognosis of stroke patients and therefore has a broad market prospect.